Literature DB >> 28230359

Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor.

Carlos A Sanhueza1,2, Michael M Baksh1,2, Benjamin Thuma3, Marc D Roy4, Sanjay Dutta2, Cathy Préville3, Boris A Chrunyk3, Kevin Beaumont5, Robert Dullea6, Mark Ammirati3, Shenping Liu3, David Gebhard3, James E Finley4, Christopher T Salatto6, Amanda King-Ahmad3, Ingrid Stock3, Karen Atkinson3, Benjamin Reidich6, Wen Lin3, Rajesh Kumar7, Meihua Tu5, Elnaz Menhaji-Klotz5, David A Price5, Spiros Liras5, M G Finn1,2, Vincent Mascitti3.   

Abstract

A compact and stable bicyclic bridged ketal was developed as a ligand for the asialoglycoprotein receptor (ASGPR). This compound showed excellent ligand efficiency, and the molecular details of binding were revealed by the first X-ray crystal structures of ligand-bound ASGPR. This analogue was used to make potent di- and trivalent binders of ASGPR. Extensive characterization of the function of these compounds showed rapid ASGPR-dependent cellular uptake in vitro and high levels of liver/plasma selectivity in vivo. Assessment of the biodistribution in rodents of a prototypical Alexa647-labeled trivalent conjugate showed selective hepatocyte targeting with no detectable distribution in nonparenchymal cells. This molecule also exhibited increased ASGPR-directed hepatocellular uptake and prolonged retention compared to a similar GalNAc derived trimer conjugate. Selective release in the liver of a passively permeable small-molecule cargo was achieved by retro-Diels-Alder cleavage of an oxanorbornadiene linkage, presumably upon encountering intracellular thiol. Therefore, the multicomponent construct described here represents a highly efficient delivery vehicle to hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28230359      PMCID: PMC6991140          DOI: 10.1021/jacs.6b12964

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  46 in total

Review 1.  Affinity enhancement by multivalent lectin-carbohydrate interaction.

Authors:  R T Lee; Y C Lee
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 2.916

2.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

3.  Glycomimetic ligands for the human asialoglycoprotein receptor.

Authors:  Sreeman K Mamidyala; Sanjay Dutta; Boris A Chrunyk; Cathy Préville; Hong Wang; Jane M Withka; Alexander McColl; Timothy A Subashi; Steven J Hawrylik; Matthew C Griffor; Sung Kim; Jeffrey A Pfefferkorn; David A Price; Elnaz Menhaji-Klotz; Vincent Mascitti; M G Finn
Journal:  J Am Chem Soc       Date:  2012-01-24       Impact factor: 15.419

4.  Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain.

Authors:  A R Kolatkar; A K Leung; R Isecke; R Brossmer; K Drickamer; W I Weis
Journal:  J Biol Chem       Date:  1998-07-31       Impact factor: 5.157

Review 5.  Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.

Authors:  Anisha A D'Souza; Padma V Devarajan
Journal:  J Control Release       Date:  2015-02-18       Impact factor: 9.776

6.  The isolation and properties of a rabbit liver binding protein specific for asialoglycoproteins.

Authors:  R L Hudgin; W E Pricer; G Ashwell; R J Stockert; A G Morell
Journal:  J Biol Chem       Date:  1974-09-10       Impact factor: 5.157

7.  Degradable conjugates from oxanorbornadiene reagents.

Authors:  Alexander A Kislukhin; Cody J Higginson; Vu P Hong; M G Finn
Journal:  J Am Chem Soc       Date:  2012-03-28       Impact factor: 15.419

8.  Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.

Authors:  A David; P Kopecková; Tamara Minko; Abraham Rubinstein; J Kopecek
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

9.  The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls.

Authors:  Dries Vercauteren; Roosmarijn E Vandenbroucke; Arwyn T Jones; Joanna Rejman; Joseph Demeester; Stefaan C De Smedt; Niek N Sanders; Kevin Braeckmans
Journal:  Mol Ther       Date:  2009-12-15       Impact factor: 11.454

10.  Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.

Authors:  Colby S Shemesh; Rosie Z Yu; Hans J Gaus; Sarah Greenlee; Noah Post; Karsten Schmidt; Michael T Migawa; Punit P Seth; Thomas A Zanardi; Thazha P Prakash; Eric E Swayze; Scott P Henry; Yanfeng Wang
Journal:  Mol Ther Nucleic Acids       Date:  2016-05-10       Impact factor: 10.183

View more
  9 in total

1.  GlcNAc Conjugated Atorvastatin with Enhanced Water Solubility and Cellular Internalization.

Authors:  Xinfu Zhang; Xiaofang Chen; Weiyu Zhao; Chunxi Zeng; Xiao Luo; Wenqing Li; Bin Li; Justin Jiang; Yizhou Dong
Journal:  Bioconjug Chem       Date:  2017-08-07       Impact factor: 4.774

2.  Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver.

Authors:  Cory D Sago; Melissa P Lokugamage; David Loughrey; Kevin E Lindsay; Robert Hincapie; Brandon R Krupczak; Sujay Kalathoor; Manaka Sato; Elisa Schrader Echeverri; Jordan P Fitzgerald; Zubao Gan; Lena Gamboa; Kalina Paunovska; Carlos A Sanhueza; Marine Z C Hatit; M G Finn; Philip J Santangelo; James E Dahlman
Journal:  Nat Biomed Eng       Date:  2022-02-21       Impact factor: 29.234

3.  Novel β-Cyclodextrin-Based Heptavalent Glycyrrhetinic Acid Conjugates: Synthesis, Characterization, and Anti-Influenza Activity.

Authors:  Shuobin Liang; Xinyuan Ma; Man Li; Yanliang Yi; Qianqian Gao; Yongmin Zhang; Lihe Zhang; Demin Zhou; Sulong Xiao
Journal:  Front Chem       Date:  2022-04-12       Impact factor: 5.545

4.  Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing.

Authors:  Romain Rouet; Benjamin A Thuma; Marc D Roy; Nathanael G Lintner; David M Rubitski; James E Finley; Hanna M Wisniewska; Rima Mendonsa; Ariana Hirsh; Lorena de Oñate; Joan Compte Barrón; Thomas J McLellan; Justin Bellenger; Xidong Feng; Alison Varghese; Boris A Chrunyk; Kris Borzilleri; Kevin D Hesp; Kaihong Zhou; Nannan Ma; Meihua Tu; Robert Dullea; Kim F McClure; Ross C Wilson; Spiros Liras; Vincent Mascitti; Jennifer A Doudna
Journal:  J Am Chem Soc       Date:  2018-05-18       Impact factor: 15.419

5.  The Influence of Substitution on Thiol-Induced Oxanorbornadiene Fragmentation.

Authors:  Lucrezia De Pascalis; Mei-Kwan Yau; Dennis Svatunek; Zhuoting Tan; Srinivas Tekkam; K N Houk; M G Finn
Journal:  Org Lett       Date:  2021-04-14       Impact factor: 6.072

Review 6.  Therapeutic siRNA: state of the art.

Authors:  Bo Hu; Liping Zhong; Yuanyu Huang; Yuhua Weng; Ling Peng; Yongxiang Zhao; Xing-Jie Liang
Journal:  Signal Transduct Target Ther       Date:  2020-06-19

7.  Ligand Conjugated Multimeric siRNAs Enable Enhanced Uptake and Multiplexed Gene Silencing.

Authors:  Jonathan M Brown; James E Dahlman; Kristin K Neuman; Carla A H Prata; Monika C Krampert; Philipp M Hadwiger; Hans-Peter Vornlocher
Journal:  Nucleic Acid Ther       Date:  2019-08-08       Impact factor: 5.486

Review 8.  Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy.

Authors:  Yongbing Sun; Wen Ma; Yuanyuan Yang; Mengxue He; Aimin Li; Lei Bai; Bin Yu; Zhiqiang Yu
Journal:  Asian J Pharm Sci       Date:  2019-06-12       Impact factor: 6.598

9.  Mega-High-Throughput Screening Platform for the Discovery of Biologically Relevant Sequence-Defined Non-Natural Polymers.

Authors:  Michal Avital-Shmilovici; Xiaohe Liu; Thomas Shaler; Andrew Lowenthal; Pauline Bourbon; Janey Snider; Arlyn Tambo-Ong; Claire Repellin; Kenya Yniguez; Lidia Sambucetti; Peter B Madrid; Nathan Collins
Journal:  ACS Cent Sci       Date:  2022-01-11       Impact factor: 14.553

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.